Navigation Links
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Date:12/5/2011

ven PDE isozymes, in comparison with sildenafil, tadalafil and vardenafil. Dr. Wang concluded that, in-vitro, avanafil strongly inhibited PDE5 while demonstrating the highest aggregate selectivity in its class against all other PDE isozymes. 

Lastly, Mark Allison, MD, Certified Physician Investigator from Celerion in Tempe, Arizona presented a poster entitled:

Pharmacokinetics of Avanafil, a Novel, Rapidly Absorbed, Selective PDE5 Inhibitor for the Treatment of Mild to Severe Erectile Dysfunction

In his presentation, Dr. Allison summarized the PK results from several avanafil phase 1 studies which indicated rapid absorption (tmax 30-45 min), short plasma half-life (3-5 hours) and lack of accumulation following multiple dosing.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators.  VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010.  We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012.  Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea.  In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being s
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
2. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
8. New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
9. New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Resources Group finds that the Asia Pacific ... , India , Japan ... Dental implant procedure volumes will grow as physicians are increasingly trained ... key findings from Decision Resources Group,s coverage of the ... Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 ... of the American Association of Tissue Banks (AATB), ... , Chief Executive Officer. Accreditation follows ... by a specially trained AATB inspector.  It establishes ... performance within the facility meets or exceeds the ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2
... Lilly and Company (NYSE: LLY ) today ... Radiopharmaceuticals, Inc., a privately held company developing novel molecular ... chronic human diseases. The transaction, first announced on November ... and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All ...
... year, the Food and Drug Administration (FDA) approves many ... and help consumers save money. To read ... to http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm236544.htm . Sign up for ... https://service.govdelivery.com/service/subscribe.html?code=USFDA_9 . View the ...
Cached Medicine Technology:Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir 2
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Children conceived either ... the birth of a sibling could be at increased risk ... study,s lead author and an outside expert agree that the ... in autism. "Most importantly, it is important that parents ... even when pregnancies are close together or far apart," said ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... Next to lung cancer, breast cancer is the leading ... American Cancer Society. That,s why so many medical professionals ... are imperfect at best: only a minority of suspicious ... results in lots of needless worry for women and ... of additional tests, including ultrasounds and biopsies. , ...
(Date:9/30/2014)... slow the spiraling costs of drugs paid for by ... no meaningful impact on cancer chemotherapy drug costs, say ... Clinical Oncology published online today. , "We looked ... lung cancers, and did not find a substantial change ... of the recent Medicare law in 2005," says the ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s leader ... specialty practice through a unique partnership with an established ... within the company’s Shrewsbury location and will be staffed ... American Heart Center, P.C., a highly regarded practice located ... Medicine Alliance patients top notch cardiovascular care without leaving ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... FAIRFAX, Va., July 27 A new proposal from the Centers ... therapy treatments would cause many cancer centers to close, stop accepting ... patients, according to a survey conducted by ASTRO, the American Society ... technology has allowed radiation oncologists to improve cancer cure rates while ...
... , St. Jude scientists identify new ... the need for more detailed look at the complete AML genome ... The most comprehensive analysis yet of the genome of childhood acute ... blueprint, suggesting the cancer arises from just a handful of missteps, ...
... serious complications drop with intensive therapy, study shows , ... blood sugar levels and taking medications that lower blood ... significantly reduce their risk of developing the most serious ... In a study appearing in the July 27 issue ...
... , , SWIFTWATER, ... Group (EURONEXT: SAN and NYSE: SNY ), announced today ... of Fluzone((R)), Influenza Virus Vaccine. Fluzone vaccine is indicated for active ... disease caused by influenza virus subtypes A and type B contained ...
... , DENVER, July 27 ... come together to offer Chamber members a health plan solution that ... traditional and alternative medical care. Whether members choose to treat a ... regimens, the Chamber Plan,s BlueFreedom accommodates their healing preferences. Most plan ...
... , MONDAY, July 27 (HealthDay News) -- Ozone levels ... on lung function in healthy people, say U.S. researchers. , ... of up to 75 parts per billion over an eight-hour ... to mean ozone concentrations as low as 70 parts per ...
Cached Medicine News:Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 2Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 3Health News:Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey 4Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 2Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 3Health News:Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease 4Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 2Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 3Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 4Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 5Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 6Health News:Anthem Blue Cross and Blue Shield Introduces a Health Insurance Solution With a Special 'Boulder Flair' to Chamber Members 2Health News:'Safe' Ozone Levels May Not Be for Some 2
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
... The VISULAS 690s is the ... the instrument of choice for ... clinical trials, Carl Zeiss has ... in laser manufacturing to create ...
The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
Medicine Products: